Results of a multi-center phase II study of imatinib and fluorourcail/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer

被引：0
|
作者：
Schuette, K. [1 ]
Moehler, M. [2 ]
Kettner, E. [3 ]
Hegewisch-Becker, S. [4 ]
Goekkurt, E. [1 ]
Al-Batran, S. [5 ]
Steffens, C. [6 ]
Ehninger, G. [1 ]
Stoehlmacher, J. [1 ]
机构：
[1] Univ Klinikum Carl Gustav Carus, Med Klin 1, Dresden, Germany
[2] Univ Mainz Klinikum, Med Klin, Mainz, Germany
[3] Klinikum Magdeburg, Magdeburg, Germany
[4] Onkol Schwerpunkt Praxis Hamburg, Hamburg, Germany
[5] Krankenhaus Nordw, Med Klin 2, Frankfurt, Germany
[6] Onkol Praxisgemeinschaft, Stade, Germany
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71339-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：395 / 395
页数：1
相关论文
共 50 条
  • [41] Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)
    Kim, I-H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1464 - S1464
  • [42] A Phase II Study of Lenvatinib Monotherapy as Second-Line Treatment in Unresectable Biliary Tract Cancer: Primary Analysis Results
    Ikeda, Masafumi
    Sasaki, Takashi
    Morizane, Chigusa
    Mizuno, Nobumasa
    Nagashima, Fumio
    Shimizu, Satoshi
    Hayata, Nozomi
    Ikezawa, Hiroki
    Suzuki, Takuya
    Nakajima, Ryo
    Dutcus, Corina E.
    Bower, John
    Ueno, Makoto
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 115 - 115
  • [43] Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer
    Furuse, Junji
    Okusaka, Takuji
    Funakoshi, Akihiro
    Yamao, Kenji
    Nagase, Michitaka
    Ishii, Hiroshi
    Nakachi, Kohei
    Ueno, Hideki
    Ikeda, Masafumi
    Morizane, Chigusa
    Horikawa, Yuki
    Mizuno, Nobumasa
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (09) : 552 - 556
  • [44] A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer
    Junji Furuse
    Takuji Okusaka
    Shinichi Ohkawa
    Michitaka Nagase
    Akihiro Funakoshi
    Narikazu Boku
    Kenji Yamao
    Taketo Yamaguchi
    Toshiya Sato
    Cancer Chemotherapy and Pharmacology, 2009, 65 : 113 - 120
  • [45] A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer
    Furuse, Junji
    Okusaka, Takuji
    Ohkawa, Shinichi
    Nagase, Michitaka
    Funakoshi, Akihiro
    Boku, Narikazu
    Yamao, Kenji
    Yamaguchi, Taketo
    Sato, Toshiya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 65 (01) : 113 - 120
  • [46] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] A PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH S-1 AND OXALIPLATIN IN PATIENTS WITH RECURRENT UNRESECTABLE OR METASTATIC BILIARY CANCER
    Jang, G.
    Kim, T. W.
    Lee, S. S.
    Sym, S. J.
    Lee, J.
    Ryu, M.
    Chang, H. M.
    Kang, Y.
    Lee, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 177 - 177
  • [48] A Phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer.
    Rosen, L
    Rosen, P
    Amado, R
    Chang, D
    Mulay, M
    Parson, M
    Laxa, B
    Langecker, P
    Gracey, S
    Siek, A
    Hannah, A
    CLINICAL CANCER RESEARCH, 1999, 5 : 3731S - 3732S
  • [49] Phase II trial evaluating a 2 weekly regimen of irinotecan (IR) and 5-FU/leucovorin (LV) in patients with metastatic pancreatic cancer refractory to chemotherapy.
    Ng, M
    Norman, AR
    Cunningham, D
    Waters, J
    Oates, J
    Ross, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 370S - 370S
  • [50] A randomised phase II study comparing irinotecan (IRI) plus leucovorin (LV) and 5-fluorouracil (5FU) versus IRI-LV-5FU followed be oxaliplatin (OXA) plus LV-5FU in patients with previously untreated metastatic colorectal cancer (CRC).
    Kalofonos, H. P.
    Papakostas, P.
    Aravantinos, G.
    Papadimitriou, C.
    Pentheroudakis, G.
    Varthalitis, I.
    Tsavdaridis, D.
    Syrigos, K.
    Kosmidis, P.
    Fountzilas, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 166S - 166S
12345